Tianjin ACCENDATECH Edge Technology Co., LTD. (hereinafter referred to as the "Company") was established in 2008, the company has been supported by the national major new drug development project, to create a technology platform across the blood-brain barrier and drug research and development platform targeting cancer stem cells. In response to the most urgent clinical needs, we have carried out global research and development, pilot production and clinical trials of original new drugs at home and abroad. The company is currently developing a number of candidate new drug varieties, of which the exclusive development of small molecule immunomodulator ACT001 can well cross the blood-brain barrier and enter the brain in large quantities. Immunomodulators (such as lenalidomide) often have broad application prospects in cancer, inflammation and fibrosis, but among the candidates in global marketing and clinical trials, immunomodulators that can enter the brain are very rare. ACT001 was granted orphan drug status in the United States in 2017, is one of the top 10 varieties in China to obtain FDA orphan drug status, and obtained EU orphan drug status without defense in 2018. In 2021, ACT001 was approved by the US FDA as a rare disease in children, which is the first rare disease in children independently developed in China. The results of the ACT001-related clinical trials were presented in three ASCO conference posters in 2018/2021 and in the SNO Conference lecture presentations in 2021. ACT001 has been approved in eight phase 1b/2a or 2 trials and one phase 2b/3 trial in China, the United States and Australia. The company is not only engaged in the development of new drugs for refractory rare diseases and rare diseases in children, but also vigorously promotes the expansion of indications with broad market prospects, urgent clinical needs and few competitive drugs, including radiotherapy for attenuated toxicity and sensitization, organ fibrosis and so on. Suntech is committed to gradually building a multinational pharmaceutical group integrating research and development, production and sales.